PHYTOMEDICINE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2109322, encodeId=cb8421093223c, content=偏重的研究方向：中药单体 经验分享：请问reviewer invited 2w后，decision in process 是啥意思啊要拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109d8446709, createdName=ms9000000320168864, createdTime=Sat Jan 07 21:53:44 CST 2023, time=2023-01-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159533, encodeId=f7c9215953315, content=偏重的研究方向：中药药理;中药复方 经验分享：请问审稿人2+是几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581a8113734, createdName=ms3000000915988761, createdTime=Mon Sep 25 08:03:26 CST 2023, time=2023-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决： (X) Author agreement (has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!)) The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory. (https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf) (X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes. (X) Figure legends. Only text; before figures , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=853894, encodeId=7268853894f0, content=审稿速度:4.0 经验分享：请问这个杂志有decision in process状态吗？我的被主编和另外一个编辑审核后，就出现了这个状态decision in process , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Sun Sep 22 10:33:39 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156128, encodeId=c0212156128b1, content=二审审稿人说已经修改但没有具体意见，编辑还给了修回，回复邮件编辑也不回，感觉跟之前的编辑好像不一样，这个不是很负责，根本没有看审稿人的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aed05086398, createdName=145c3ab9m71暂无昵称, createdTime=Tue Sep 05 06:37:40 CST 2023, time=2023-09-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1198237, encodeId=3db6119823e3f, content=偏重的研究方向：中药单体 经验分享：咨询各位老师，reviewer invited一般多久？目前已经一个月了，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7dd357230, createdName=kkrrkf, createdTime=Tue Mar 01 04:07:35 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152921, encodeId=5d56215292109, content=有人知道返修under review后又再次under editor assessment是咋回事吗？之前初审的时候review后没有这个过程。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a428573121, createdName=ms7000001625661097, createdTime=Tue Aug 15 20:00:03 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2153099, encodeId=a8222153099ee, content=请问各位，第一次投稿的editor assessment大概多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Aug 16 22:06:19 CST 2023, time=2023-08-16, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151446, encodeId=bfb121514467b, content=偏重的研究方向：中药活性成分 经验分享：可以投综述吗，还是邀请才能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Aug 05 23:40:07 CST 2023, time=2023-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2157423, encodeId=6284215e4237e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：中药单体;基础研究;作用机制 经验分享：2023.2.8投稿，2023.9.7修回，9.9接收。期间经历2次修稿。审稿时间很快，主要是找审稿人花时间。编辑送了2个审稿人，回复后，出现decision in process，以为要接受了，结果又出现reviewer invited，在邀请了2位审稿人。但是总体很流畅。感谢编辑审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d2991721013, createdName=William chen, createdTime=Tue Sep 12 22:46:29 CST 2023, time=2023-09-12, status=1, ipAttribution=广东省)]

2023-01-07 ms9000000320168864 来自江苏省

偏重的研究方向：中药单体
经验分享：请问reviewer invited 2w后，decision in process 是啥意思啊要拒稿吗

30 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2109322, encodeId=cb8421093223c, content=偏重的研究方向：中药单体 经验分享：请问reviewer invited 2w后，decision in process 是啥意思啊要拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109d8446709, createdName=ms9000000320168864, createdTime=Sat Jan 07 21:53:44 CST 2023, time=2023-01-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159533, encodeId=f7c9215953315, content=偏重的研究方向：中药药理;中药复方 经验分享：请问审稿人2+是几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581a8113734, createdName=ms3000000915988761, createdTime=Mon Sep 25 08:03:26 CST 2023, time=2023-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决： (X) Author agreement (has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!)) The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory. (https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf) (X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes. (X) Figure legends. Only text; before figures , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=853894, encodeId=7268853894f0, content=审稿速度:4.0 经验分享：请问这个杂志有decision in process状态吗？我的被主编和另外一个编辑审核后，就出现了这个状态decision in process , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Sun Sep 22 10:33:39 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156128, encodeId=c0212156128b1, content=二审审稿人说已经修改但没有具体意见，编辑还给了修回，回复邮件编辑也不回，感觉跟之前的编辑好像不一样，这个不是很负责，根本没有看审稿人的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aed05086398, createdName=145c3ab9m71暂无昵称, createdTime=Tue Sep 05 06:37:40 CST 2023, time=2023-09-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1198237, encodeId=3db6119823e3f, content=偏重的研究方向：中药单体 经验分享：咨询各位老师，reviewer invited一般多久？目前已经一个月了，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7dd357230, createdName=kkrrkf, createdTime=Tue Mar 01 04:07:35 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152921, encodeId=5d56215292109, content=有人知道返修under review后又再次under editor assessment是咋回事吗？之前初审的时候review后没有这个过程。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a428573121, createdName=ms7000001625661097, createdTime=Tue Aug 15 20:00:03 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2153099, encodeId=a8222153099ee, content=请问各位，第一次投稿的editor assessment大概多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Aug 16 22:06:19 CST 2023, time=2023-08-16, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151446, encodeId=bfb121514467b, content=偏重的研究方向：中药活性成分 经验分享：可以投综述吗，还是邀请才能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Aug 05 23:40:07 CST 2023, time=2023-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2157423, encodeId=6284215e4237e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：中药单体;基础研究;作用机制 经验分享：2023.2.8投稿，2023.9.7修回，9.9接收。期间经历2次修稿。审稿时间很快，主要是找审稿人花时间。编辑送了2个审稿人，回复后，出现decision in process，以为要接受了，结果又出现reviewer invited，在邀请了2位审稿人。但是总体很流畅。感谢编辑审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d2991721013, createdName=William chen, createdTime=Tue Sep 12 22:46:29 CST 2023, time=2023-09-12, status=1, ipAttribution=广东省)]

2023-09-25 ms3000000915988761

偏重的研究方向：中药药理;中药复方
经验分享：请问审稿人2+是几个审稿人？

7 0

[GetPortalCommentsPageByObjectIdResponse(id=2109322, encodeId=cb8421093223c, content=偏重的研究方向：中药单体 经验分享：请问reviewer invited 2w后，decision in process 是啥意思啊要拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109d8446709, createdName=ms9000000320168864, createdTime=Sat Jan 07 21:53:44 CST 2023, time=2023-01-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159533, encodeId=f7c9215953315, content=偏重的研究方向：中药药理;中药复方 经验分享：请问审稿人2+是几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581a8113734, createdName=ms3000000915988761, createdTime=Mon Sep 25 08:03:26 CST 2023, time=2023-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决： (X) Author agreement (has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!)) The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory. (https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf) (X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes. (X) Figure legends. Only text; before figures , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=853894, encodeId=7268853894f0, content=审稿速度:4.0 经验分享：请问这个杂志有decision in process状态吗？我的被主编和另外一个编辑审核后，就出现了这个状态decision in process , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Sun Sep 22 10:33:39 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156128, encodeId=c0212156128b1, content=二审审稿人说已经修改但没有具体意见，编辑还给了修回，回复邮件编辑也不回，感觉跟之前的编辑好像不一样，这个不是很负责，根本没有看审稿人的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aed05086398, createdName=145c3ab9m71暂无昵称, createdTime=Tue Sep 05 06:37:40 CST 2023, time=2023-09-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1198237, encodeId=3db6119823e3f, content=偏重的研究方向：中药单体 经验分享：咨询各位老师，reviewer invited一般多久？目前已经一个月了，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7dd357230, createdName=kkrrkf, createdTime=Tue Mar 01 04:07:35 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152921, encodeId=5d56215292109, content=有人知道返修under review后又再次under editor assessment是咋回事吗？之前初审的时候review后没有这个过程。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a428573121, createdName=ms7000001625661097, createdTime=Tue Aug 15 20:00:03 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2153099, encodeId=a8222153099ee, content=请问各位，第一次投稿的editor assessment大概多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Aug 16 22:06:19 CST 2023, time=2023-08-16, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151446, encodeId=bfb121514467b, content=偏重的研究方向：中药活性成分 经验分享：可以投综述吗，还是邀请才能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Aug 05 23:40:07 CST 2023, time=2023-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2157423, encodeId=6284215e4237e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：中药单体;基础研究;作用机制 经验分享：2023.2.8投稿，2023.9.7修回，9.9接收。期间经历2次修稿。审稿时间很快，主要是找审稿人花时间。编辑送了2个审稿人，回复后，出现decision in process，以为要接受了，结果又出现reviewer invited，在邀请了2位审稿人。但是总体很流畅。感谢编辑审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d2991721013, createdName=William chen, createdTime=Tue Sep 12 22:46:29 CST 2023, time=2023-09-12, status=1, ipAttribution=广东省)]

2023-05-10 ms1000001447770011 来自浙江省

想要询问一下以下情况如何解决：

(X) Author agreement
(has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!))
The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory.
(https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf)
(X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes.
(X) Figure legends. Only text; before figures

0 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2109322, encodeId=cb8421093223c, content=偏重的研究方向：中药单体 经验分享：请问reviewer invited 2w后，decision in process 是啥意思啊要拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109d8446709, createdName=ms9000000320168864, createdTime=Sat Jan 07 21:53:44 CST 2023, time=2023-01-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159533, encodeId=f7c9215953315, content=偏重的研究方向：中药药理;中药复方 经验分享：请问审稿人2+是几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581a8113734, createdName=ms3000000915988761, createdTime=Mon Sep 25 08:03:26 CST 2023, time=2023-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决： (X) Author agreement (has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!)) The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory. (https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf) (X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes. (X) Figure legends. Only text; before figures , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=853894, encodeId=7268853894f0, content=审稿速度:4.0 经验分享：请问这个杂志有decision in process状态吗？我的被主编和另外一个编辑审核后，就出现了这个状态decision in process , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Sun Sep 22 10:33:39 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156128, encodeId=c0212156128b1, content=二审审稿人说已经修改但没有具体意见，编辑还给了修回，回复邮件编辑也不回，感觉跟之前的编辑好像不一样，这个不是很负责，根本没有看审稿人的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aed05086398, createdName=145c3ab9m71暂无昵称, createdTime=Tue Sep 05 06:37:40 CST 2023, time=2023-09-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1198237, encodeId=3db6119823e3f, content=偏重的研究方向：中药单体 经验分享：咨询各位老师，reviewer invited一般多久？目前已经一个月了，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7dd357230, createdName=kkrrkf, createdTime=Tue Mar 01 04:07:35 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152921, encodeId=5d56215292109, content=有人知道返修under review后又再次under editor assessment是咋回事吗？之前初审的时候review后没有这个过程。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a428573121, createdName=ms7000001625661097, createdTime=Tue Aug 15 20:00:03 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2153099, encodeId=a8222153099ee, content=请问各位，第一次投稿的editor assessment大概多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Aug 16 22:06:19 CST 2023, time=2023-08-16, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151446, encodeId=bfb121514467b, content=偏重的研究方向：中药活性成分 经验分享：可以投综述吗，还是邀请才能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Aug 05 23:40:07 CST 2023, time=2023-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2157423, encodeId=6284215e4237e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：中药单体;基础研究;作用机制 经验分享：2023.2.8投稿，2023.9.7修回，9.9接收。期间经历2次修稿。审稿时间很快，主要是找审稿人花时间。编辑送了2个审稿人，回复后，出现decision in process，以为要接受了，结果又出现reviewer invited，在邀请了2位审稿人。但是总体很流畅。感谢编辑审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d2991721013, createdName=William chen, createdTime=Tue Sep 12 22:46:29 CST 2023, time=2023-09-12, status=1, ipAttribution=广东省)]

2019-09-22 ms8415407993286297

审稿速度:4.0
经验分享：请问这个杂志有decision in process状态吗？我的被主编和另外一个编辑审核后，就出现了这个状态decision in process

74 19

展开19条回复

[GetPortalCommentsPageByObjectIdResponse(id=2109322, encodeId=cb8421093223c, content=偏重的研究方向：中药单体 经验分享：请问reviewer invited 2w后，decision in process 是啥意思啊要拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109d8446709, createdName=ms9000000320168864, createdTime=Sat Jan 07 21:53:44 CST 2023, time=2023-01-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159533, encodeId=f7c9215953315, content=偏重的研究方向：中药药理;中药复方 经验分享：请问审稿人2+是几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581a8113734, createdName=ms3000000915988761, createdTime=Mon Sep 25 08:03:26 CST 2023, time=2023-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决： (X) Author agreement (has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!)) The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory. (https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf) (X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes. (X) Figure legends. Only text; before figures , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=853894, encodeId=7268853894f0, content=审稿速度:4.0 经验分享：请问这个杂志有decision in process状态吗？我的被主编和另外一个编辑审核后，就出现了这个状态decision in process , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Sun Sep 22 10:33:39 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156128, encodeId=c0212156128b1, content=二审审稿人说已经修改但没有具体意见，编辑还给了修回，回复邮件编辑也不回，感觉跟之前的编辑好像不一样，这个不是很负责，根本没有看审稿人的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aed05086398, createdName=145c3ab9m71暂无昵称, createdTime=Tue Sep 05 06:37:40 CST 2023, time=2023-09-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1198237, encodeId=3db6119823e3f, content=偏重的研究方向：中药单体 经验分享：咨询各位老师，reviewer invited一般多久？目前已经一个月了，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7dd357230, createdName=kkrrkf, createdTime=Tue Mar 01 04:07:35 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152921, encodeId=5d56215292109, content=有人知道返修under review后又再次under editor assessment是咋回事吗？之前初审的时候review后没有这个过程。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a428573121, createdName=ms7000001625661097, createdTime=Tue Aug 15 20:00:03 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2153099, encodeId=a8222153099ee, content=请问各位，第一次投稿的editor assessment大概多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Aug 16 22:06:19 CST 2023, time=2023-08-16, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151446, encodeId=bfb121514467b, content=偏重的研究方向：中药活性成分 经验分享：可以投综述吗，还是邀请才能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Aug 05 23:40:07 CST 2023, time=2023-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2157423, encodeId=6284215e4237e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：中药单体;基础研究;作用机制 经验分享：2023.2.8投稿，2023.9.7修回，9.9接收。期间经历2次修稿。审稿时间很快，主要是找审稿人花时间。编辑送了2个审稿人，回复后，出现decision in process，以为要接受了，结果又出现reviewer invited，在邀请了2位审稿人。但是总体很流畅。感谢编辑审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d2991721013, createdName=William chen, createdTime=Tue Sep 12 22:46:29 CST 2023, time=2023-09-12, status=1, ipAttribution=广东省)]

2023-09-05 145c3ab9m71暂无昵称来自河南省

二审审稿人说已经修改但没有具体意见，编辑还给了修回，回复邮件编辑也不回，感觉跟之前的编辑好像不一样，这个不是很负责，根本没有看审稿人的意见

18 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2109322, encodeId=cb8421093223c, content=偏重的研究方向：中药单体 经验分享：请问reviewer invited 2w后，decision in process 是啥意思啊要拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109d8446709, createdName=ms9000000320168864, createdTime=Sat Jan 07 21:53:44 CST 2023, time=2023-01-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159533, encodeId=f7c9215953315, content=偏重的研究方向：中药药理;中药复方 经验分享：请问审稿人2+是几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581a8113734, createdName=ms3000000915988761, createdTime=Mon Sep 25 08:03:26 CST 2023, time=2023-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决： (X) Author agreement (has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!)) The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory. (https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf) (X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes. (X) Figure legends. Only text; before figures , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=853894, encodeId=7268853894f0, content=审稿速度:4.0 经验分享：请问这个杂志有decision in process状态吗？我的被主编和另外一个编辑审核后，就出现了这个状态decision in process , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Sun Sep 22 10:33:39 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156128, encodeId=c0212156128b1, content=二审审稿人说已经修改但没有具体意见，编辑还给了修回，回复邮件编辑也不回，感觉跟之前的编辑好像不一样，这个不是很负责，根本没有看审稿人的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aed05086398, createdName=145c3ab9m71暂无昵称, createdTime=Tue Sep 05 06:37:40 CST 2023, time=2023-09-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1198237, encodeId=3db6119823e3f, content=偏重的研究方向：中药单体 经验分享：咨询各位老师，reviewer invited一般多久？目前已经一个月了，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7dd357230, createdName=kkrrkf, createdTime=Tue Mar 01 04:07:35 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152921, encodeId=5d56215292109, content=有人知道返修under review后又再次under editor assessment是咋回事吗？之前初审的时候review后没有这个过程。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a428573121, createdName=ms7000001625661097, createdTime=Tue Aug 15 20:00:03 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2153099, encodeId=a8222153099ee, content=请问各位，第一次投稿的editor assessment大概多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Aug 16 22:06:19 CST 2023, time=2023-08-16, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151446, encodeId=bfb121514467b, content=偏重的研究方向：中药活性成分 经验分享：可以投综述吗，还是邀请才能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Aug 05 23:40:07 CST 2023, time=2023-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2157423, encodeId=6284215e4237e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：中药单体;基础研究;作用机制 经验分享：2023.2.8投稿，2023.9.7修回，9.9接收。期间经历2次修稿。审稿时间很快，主要是找审稿人花时间。编辑送了2个审稿人，回复后，出现decision in process，以为要接受了，结果又出现reviewer invited，在邀请了2位审稿人。但是总体很流畅。感谢编辑审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d2991721013, createdName=William chen, createdTime=Tue Sep 12 22:46:29 CST 2023, time=2023-09-12, status=1, ipAttribution=广东省)]

2022-03-01 kkrrkf

偏重的研究方向：中药单体
经验分享：咨询各位老师，reviewer invited一般多久？目前已经一个月了，谢谢

273 24

展开24条回复

[GetPortalCommentsPageByObjectIdResponse(id=2109322, encodeId=cb8421093223c, content=偏重的研究方向：中药单体 经验分享：请问reviewer invited 2w后，decision in process 是啥意思啊要拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109d8446709, createdName=ms9000000320168864, createdTime=Sat Jan 07 21:53:44 CST 2023, time=2023-01-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159533, encodeId=f7c9215953315, content=偏重的研究方向：中药药理;中药复方 经验分享：请问审稿人2+是几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581a8113734, createdName=ms3000000915988761, createdTime=Mon Sep 25 08:03:26 CST 2023, time=2023-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决： (X) Author agreement (has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!)) The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory. (https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf) (X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes. (X) Figure legends. Only text; before figures , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=853894, encodeId=7268853894f0, content=审稿速度:4.0 经验分享：请问这个杂志有decision in process状态吗？我的被主编和另外一个编辑审核后，就出现了这个状态decision in process , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Sun Sep 22 10:33:39 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156128, encodeId=c0212156128b1, content=二审审稿人说已经修改但没有具体意见，编辑还给了修回，回复邮件编辑也不回，感觉跟之前的编辑好像不一样，这个不是很负责，根本没有看审稿人的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aed05086398, createdName=145c3ab9m71暂无昵称, createdTime=Tue Sep 05 06:37:40 CST 2023, time=2023-09-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1198237, encodeId=3db6119823e3f, content=偏重的研究方向：中药单体 经验分享：咨询各位老师，reviewer invited一般多久？目前已经一个月了，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7dd357230, createdName=kkrrkf, createdTime=Tue Mar 01 04:07:35 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152921, encodeId=5d56215292109, content=有人知道返修under review后又再次under editor assessment是咋回事吗？之前初审的时候review后没有这个过程。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a428573121, createdName=ms7000001625661097, createdTime=Tue Aug 15 20:00:03 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2153099, encodeId=a8222153099ee, content=请问各位，第一次投稿的editor assessment大概多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Aug 16 22:06:19 CST 2023, time=2023-08-16, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151446, encodeId=bfb121514467b, content=偏重的研究方向：中药活性成分 经验分享：可以投综述吗，还是邀请才能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Aug 05 23:40:07 CST 2023, time=2023-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2157423, encodeId=6284215e4237e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：中药单体;基础研究;作用机制 经验分享：2023.2.8投稿，2023.9.7修回，9.9接收。期间经历2次修稿。审稿时间很快，主要是找审稿人花时间。编辑送了2个审稿人，回复后，出现decision in process，以为要接受了，结果又出现reviewer invited，在邀请了2位审稿人。但是总体很流畅。感谢编辑审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d2991721013, createdName=William chen, createdTime=Tue Sep 12 22:46:29 CST 2023, time=2023-09-12, status=1, ipAttribution=广东省)]

2023-08-15 ms7000001625661097 来自浙江省

有人知道返修under review后又再次under editor assessment是咋回事吗？之前初审的时候review后没有这个过程。

12 20

展开20条回复

[GetPortalCommentsPageByObjectIdResponse(id=2109322, encodeId=cb8421093223c, content=偏重的研究方向：中药单体 经验分享：请问reviewer invited 2w后，decision in process 是啥意思啊要拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109d8446709, createdName=ms9000000320168864, createdTime=Sat Jan 07 21:53:44 CST 2023, time=2023-01-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159533, encodeId=f7c9215953315, content=偏重的研究方向：中药药理;中药复方 经验分享：请问审稿人2+是几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581a8113734, createdName=ms3000000915988761, createdTime=Mon Sep 25 08:03:26 CST 2023, time=2023-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决： (X) Author agreement (has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!)) The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory. (https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf) (X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes. (X) Figure legends. Only text; before figures , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=853894, encodeId=7268853894f0, content=审稿速度:4.0 经验分享：请问这个杂志有decision in process状态吗？我的被主编和另外一个编辑审核后，就出现了这个状态decision in process , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Sun Sep 22 10:33:39 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156128, encodeId=c0212156128b1, content=二审审稿人说已经修改但没有具体意见，编辑还给了修回，回复邮件编辑也不回，感觉跟之前的编辑好像不一样，这个不是很负责，根本没有看审稿人的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aed05086398, createdName=145c3ab9m71暂无昵称, createdTime=Tue Sep 05 06:37:40 CST 2023, time=2023-09-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1198237, encodeId=3db6119823e3f, content=偏重的研究方向：中药单体 经验分享：咨询各位老师，reviewer invited一般多久？目前已经一个月了，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7dd357230, createdName=kkrrkf, createdTime=Tue Mar 01 04:07:35 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152921, encodeId=5d56215292109, content=有人知道返修under review后又再次under editor assessment是咋回事吗？之前初审的时候review后没有这个过程。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a428573121, createdName=ms7000001625661097, createdTime=Tue Aug 15 20:00:03 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2153099, encodeId=a8222153099ee, content=请问各位，第一次投稿的editor assessment大概多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Aug 16 22:06:19 CST 2023, time=2023-08-16, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151446, encodeId=bfb121514467b, content=偏重的研究方向：中药活性成分 经验分享：可以投综述吗，还是邀请才能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Aug 05 23:40:07 CST 2023, time=2023-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2157423, encodeId=6284215e4237e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：中药单体;基础研究;作用机制 经验分享：2023.2.8投稿，2023.9.7修回，9.9接收。期间经历2次修稿。审稿时间很快，主要是找审稿人花时间。编辑送了2个审稿人，回复后，出现decision in process，以为要接受了，结果又出现reviewer invited，在邀请了2位审稿人。但是总体很流畅。感谢编辑审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d2991721013, createdName=William chen, createdTime=Tue Sep 12 22:46:29 CST 2023, time=2023-09-12, status=1, ipAttribution=广东省)]

2023-08-16 llllkn 来自浙江省

请问各位，第一次投稿的editor assessment大概多久呀？

11 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2109322, encodeId=cb8421093223c, content=偏重的研究方向：中药单体 经验分享：请问reviewer invited 2w后，decision in process 是啥意思啊要拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109d8446709, createdName=ms9000000320168864, createdTime=Sat Jan 07 21:53:44 CST 2023, time=2023-01-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159533, encodeId=f7c9215953315, content=偏重的研究方向：中药药理;中药复方 经验分享：请问审稿人2+是几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581a8113734, createdName=ms3000000915988761, createdTime=Mon Sep 25 08:03:26 CST 2023, time=2023-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决： (X) Author agreement (has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!)) The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory. (https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf) (X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes. (X) Figure legends. Only text; before figures , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=853894, encodeId=7268853894f0, content=审稿速度:4.0 经验分享：请问这个杂志有decision in process状态吗？我的被主编和另外一个编辑审核后，就出现了这个状态decision in process , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Sun Sep 22 10:33:39 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156128, encodeId=c0212156128b1, content=二审审稿人说已经修改但没有具体意见，编辑还给了修回，回复邮件编辑也不回，感觉跟之前的编辑好像不一样，这个不是很负责，根本没有看审稿人的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aed05086398, createdName=145c3ab9m71暂无昵称, createdTime=Tue Sep 05 06:37:40 CST 2023, time=2023-09-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1198237, encodeId=3db6119823e3f, content=偏重的研究方向：中药单体 经验分享：咨询各位老师，reviewer invited一般多久？目前已经一个月了，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7dd357230, createdName=kkrrkf, createdTime=Tue Mar 01 04:07:35 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152921, encodeId=5d56215292109, content=有人知道返修under review后又再次under editor assessment是咋回事吗？之前初审的时候review后没有这个过程。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a428573121, createdName=ms7000001625661097, createdTime=Tue Aug 15 20:00:03 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2153099, encodeId=a8222153099ee, content=请问各位，第一次投稿的editor assessment大概多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Aug 16 22:06:19 CST 2023, time=2023-08-16, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151446, encodeId=bfb121514467b, content=偏重的研究方向：中药活性成分 经验分享：可以投综述吗，还是邀请才能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Aug 05 23:40:07 CST 2023, time=2023-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2157423, encodeId=6284215e4237e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：中药单体;基础研究;作用机制 经验分享：2023.2.8投稿，2023.9.7修回，9.9接收。期间经历2次修稿。审稿时间很快，主要是找审稿人花时间。编辑送了2个审稿人，回复后，出现decision in process，以为要接受了，结果又出现reviewer invited，在邀请了2位审稿人。但是总体很流畅。感谢编辑审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d2991721013, createdName=William chen, createdTime=Tue Sep 12 22:46:29 CST 2023, time=2023-09-12, status=1, ipAttribution=广东省)]

2023-08-05 P拾荒者来自浙江省

偏重的研究方向：中药活性成分
经验分享：可以投综述吗，还是邀请才能

13 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2109322, encodeId=cb8421093223c, content=偏重的研究方向：中药单体 经验分享：请问reviewer invited 2w后，decision in process 是啥意思啊要拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109d8446709, createdName=ms9000000320168864, createdTime=Sat Jan 07 21:53:44 CST 2023, time=2023-01-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159533, encodeId=f7c9215953315, content=偏重的研究方向：中药药理;中药复方 经验分享：请问审稿人2+是几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581a8113734, createdName=ms3000000915988761, createdTime=Mon Sep 25 08:03:26 CST 2023, time=2023-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决： (X) Author agreement (has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!)) The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory. (https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf) (X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes. (X) Figure legends. Only text; before figures , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=853894, encodeId=7268853894f0, content=审稿速度:4.0 经验分享：请问这个杂志有decision in process状态吗？我的被主编和另外一个编辑审核后，就出现了这个状态decision in process , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Sun Sep 22 10:33:39 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156128, encodeId=c0212156128b1, content=二审审稿人说已经修改但没有具体意见，编辑还给了修回，回复邮件编辑也不回，感觉跟之前的编辑好像不一样，这个不是很负责，根本没有看审稿人的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aed05086398, createdName=145c3ab9m71暂无昵称, createdTime=Tue Sep 05 06:37:40 CST 2023, time=2023-09-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1198237, encodeId=3db6119823e3f, content=偏重的研究方向：中药单体 经验分享：咨询各位老师，reviewer invited一般多久？目前已经一个月了，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7dd357230, createdName=kkrrkf, createdTime=Tue Mar 01 04:07:35 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152921, encodeId=5d56215292109, content=有人知道返修under review后又再次under editor assessment是咋回事吗？之前初审的时候review后没有这个过程。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a428573121, createdName=ms7000001625661097, createdTime=Tue Aug 15 20:00:03 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2153099, encodeId=a8222153099ee, content=请问各位，第一次投稿的editor assessment大概多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Aug 16 22:06:19 CST 2023, time=2023-08-16, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151446, encodeId=bfb121514467b, content=偏重的研究方向：中药活性成分 经验分享：可以投综述吗，还是邀请才能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Aug 05 23:40:07 CST 2023, time=2023-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2157423, encodeId=6284215e4237e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：中药单体;基础研究;作用机制 经验分享：2023.2.8投稿，2023.9.7修回，9.9接收。期间经历2次修稿。审稿时间很快，主要是找审稿人花时间。编辑送了2个审稿人，回复后，出现decision in process，以为要接受了，结果又出现reviewer invited，在邀请了2位审稿人。但是总体很流畅。感谢编辑审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d2991721013, createdName=William chen, createdTime=Tue Sep 12 22:46:29 CST 2023, time=2023-09-12, status=1, ipAttribution=广东省)]

2023-09-12 William chen 来自广东省

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：中药单体;基础研究;作用机制
经验分享：2023.2.8投稿，2023.9.7修回，9.9接收。期间经历2次修稿。审稿时间很快，主要是找审稿人花时间。编辑送了2个审稿人，回复后，出现decision in process，以为要接受了，结果又出现reviewer invited，在邀请了2位审稿人。但是总体很流畅。感谢编辑审稿人！

12 0

内科

外科

专科科室

热点

按科室浏览

科研工具

写作工具

其他工具

平台业务解决方案

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务